Stock Details
REGN is Regeneron Pharmaceuticals, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 678.76$. Average daily volumn in 3 months 649.35k. Market cap 72.62B

Stock symbol : REGN. Exchange : NasdaqGS. Currency : USD
Lastest price : 661.14$. Total volume : 544.23k. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

Regeneron Pharmaceuticals, Inc. (REGN)
Last Price

Previous Close657.15
Day Range647.54-664.85
Bid645.63 x 800
Ask662.89 x 800
Average Volume649.35k
Market Cap72.62B
52 Week Range492.13-747.42
Trailing P/E9.40
Foward P/E14.89
Dividend (Yield %)N/A
Ex-Dividend DateN/A

Financial Details

According to Regeneron Pharmaceuticals, Inc.'s financial reports the company's revenue in 2021 were 16.07B an decrease( +100%) over the years 2020 revenue that were of 8.5B. In 2021 the company's total earnings were 8.08B while total earnings in 2020 were 3.51B( +166.67%).

Loading ...


Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vei... n occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Market Cap:
Total Assets:
Total Cash:

News about "Regeneron Pharmaceuticals, Inc."


FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

Source from : Benzinga on - 14 hours ago

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofiโ€™s (NASDAQ: SNY) lead drug candidate Dupixentยฎ (dupilumab) 300 mg weekly for patients ...See details»


Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of โ€œBuyโ€ by Analysts

Source from : Defense World - 6 days ago

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN โ€“ Get Rating) has received a consensus recommendation of โ€œBuyโ€ from the twenty analysts that are covering the stock, reports. One research ...See details»

FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment

Source from : MarketWatch - 15 hours ago

By Michael Dabaie The Food and Drug Administration said it granted to Regeneron Pharmaceuticals Inc. approval of Dupixent to treat inflammatory ...See details»

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of โ€œBuyโ€ from Analysts

Source from : Defense World - 6 days ago

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN โ€“ Get Rating) has been given an average rating of โ€œBuyโ€ by the twenty research firms that are presently covering the company, MarketBeat Ratings reports.See details»

Is Regeneron In Trouble After Sales Declined 40% In a Single Quarter?

Source from : Nasdaq - 8 days ago

and Regeneron Pharmaceuticals wasn't one of them ... herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by ...See details»

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Arthur F. Ryan Sells 100 Shares of Stock

Source from : ETF Daily News - 17 days ago

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN โ€“ Get Rating) Director Arthur F. Ryan sold 100 shares of the businessโ€™s stock in a transaction dated Monday, May 2nd. The stock was sold at an ...See details»

Regeneron Pharmaceuticals, Inc.'s (REGN) CEO Leonard Schleifer on Q1 2022 Results - Earnings Call Transcript

Source from : Seeking Alpha - 16 days ago

Regeneron does not undertake any obligation ... nor a solicitation of an offer to sell securities of Checkmate Pharmaceuticals Inc. In connection with the tender offer for Checkmate stock ...See details»


Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

Source from : YAHOO!Finance - 8 days ago

Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (โ€œCheckmateโ€), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to ...See details»

Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur

Source from : Associated Press - 3 days ago

Stine Seed Farms joins Mayo Clinic, Mirae Asset, Regeneron Pharmaceuticals Inc., Southeast Minnesota Capital Fund (SMCF), and several high-net-worth individuals on the Vyriad investment roster. This ...See details»

Regeneron makes $250M bid to buy pharmaceuticals firm

Source from : Times Union - 1 month ago

This is a carousel. Use Next and Previous buttons to navigate RENSSELAER - Regeneron Pharmaceuticals Inc. is moving to acquire Checkmate Pharmaceuticals in a $250 million all-cash purchase this year.See details»


High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair

Source from : Yahoo - 7 days ago

Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Robert Sansone, 17, of Fort Pierce, FL, won the $75,000 top award in the 2022 Regeneron International Science and ...See details»

Regeneron (REGN) to Buy Checkmate Pharmaceuticals for $250M

Source from : Nasdaq - 1 month ago

Regeneron Pharmaceuticals, Inc. REGN has announced that it will acquire clinical-stage biopharmaceutical Checkmate Pharmaceuticals, Inc. CMPI for $10.50 per share or $250 million. The ...See details»

Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest

Source from : - 25 days ago

Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) short percent of float has risen 6.48% since its last report. The company recently reported that it has 2.39 million shares sold short, which is 2.3% ...See details»

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Marion Mccourt Sells 1,100 Shares of Stock

Source from : ETF Daily News - 17 days ago

Regeneron Pharmaceuticals, Inc. has a 1 year low of $478.40 and a 1 year high of $747.42. The company has a market capitalization of $71.69 billion, a PE ratio of 9.16, a P/E/G ratio of 1.18 and a ...See details»